Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wilate versus Haemate P pharmacokinetics in von Willebrand disease type 3
ISRCTN12436735Phase 2Completed
- Sponsor
- Octapharma
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of von Willebrand factor concentrate and Haemate P in Type 3 von Willebrand disease, sponsored by Octapharma. Primary endpoint: In-vivo half-life of Wilate. Started Sep 2008; status: completed.
02
Drugs
von Willebrand factor concentrateHaemate P
03
Conditions
Type 3 von Willebrand disease
Beyond the preview
Go deeper on ISRCTN12436735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12436735.